FDA panel push for whooping cough vaccines

Share this article:

A U.S. advisory panel yesterday urged the approval for two new vaccines designed to boost immunity against whooping cough.
The panel said the vaccines, GlaxoSmithKline's Boostrix and Sanofi-Aventis' Adacel, appear safe and effective for use as booster shots after whooping cough immunity has waned. The FDA usually follows the recommendations of its advisory panels.
GSK is seeking to market Boostrix for people age 10 to 18, while Sanofi-Aventis wants to sell Adacel to a larger group of people age 11 to 64, according to a Reuters report.
Boostrix and Adacel are the first products to combine a whooping cough vaccine with the routine tetanus and diptheria booster shot given to adolescents.
Concern about whooping cough, also known as pertussis, has grown recently as reports of deaths from the disease are on the rise in the U.S. and older people who carry the bacteria can easily infect young, unvaccinated children.

 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.